The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 11, pp. 1745-1748. DOI 10.1345/aph.1C123
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frassetto, F
Right arrow Articles by Vincent, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frassetto, F
Right arrow Articles by Vincent, F


Research Articles

Goiter in a newborn exposed to lithium in utero

F Frassetto, F Tourneur Martel, CE Barjhoux, C Villier, BL Bot, and F Vincent

OBJECTIVE: To report a case of neonatal goiter and biological hypothyroidism in a newborn exposed to lithium in utero resulting from therapy given to the mother before and during her pregnancy. CASE SUMMARY: A male neonate, born at 37 weeks' gestation, presented with a goiter without other signs of hypothyroidism. His serum thyroid-stimulating hormone concentration was high and unbound tetrathyroxine concentration was low, indicating that chronic exposure to lithium was present. Oral thyroxine treatment was initiated when the infant was 3 days old and continued for 11 weeks. Treatment was effective in reducing the goiter and hormone concentrations, and allowing normal growth and psychomotor development during the following 3.5 months. Other drugs taken by the mother during pregnancy are not known to induce thyroid abnormalities. DISCUSSION: Lithium is used for prophylaxis and treatment of bipolar disorder. Goiter and hypothyroidism in adults have been described in patients treated with lithium; thyroid disorders are reversible if lithium is discontinued. Few cases of goiter and hypothyroidism have been reported in newborns exposed to lithium in utero. In our patient, congenital hypothyroidism required longer thyroxine treatment than lithium-induced thyroid disorders. The delay before improvement seems to be similar to that observed in adults. The Naranjo probability scale indicated that lithium was the probable cause of hypothyroidism resulting from in utero exposure. CONCLUSIONS: Lithium is a well-known goitrogenic agent. Thus, if lithium treatment needs to be continued during pregnancy in women with bipolar disorder, adequate screening for morphology by ultrasonography and systematic hormonal biological control in newborns are recommended.


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
C. Livingstone and H. Rampes
Lithium: a review of its metabolic adverse effects
J Psychopharmacol, May 1, 2006; 20(3): 347 - 355.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
D. J. Newport, A. C. Viguera, A. J. Beach, J. C. Ritchie, L. S. Cohen, and Z. N. Stowe
Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy
Am J Psychiatry, November 1, 2005; 162(11): 2162 - 2170.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.